

Table S1. Detailed summary of studies included in our systematic review

No	Author (year) Case number #	Article Type	Country	Age (Sex)	Other medical condition	Vaccine Type (dose)	The time interval from vaccine to symptoms	Eye	Symptoms	Baseline BCVA	Eye Examination(s)	Fundal findings	Diagnosis	Outcome
1	Al-Abri, M., et al. (2021) ²³ Case #1	CR	Oman	33 (M)	Mild obese, COVID-19 infection six months prior	mRNA vaccine (I)	2 hours	LE	Painless blurring vision	1.0 (20/20)	IOP, FE, OCT	Optic disc swelling, diffuse intraretinal hemorrhages in 4 quadrants, tortuous vascular, cotton wool spots in the inferior and superior temporal arcades, intraretinal and subretinal fluid, ME	CRVO	BCVA remained 1,0 (20/20), and resolution of ME at 4 weeks follow up after Rivaroxaban 15mg every 12 hr for 3 weeks followed by 20mg once daily thereafter, and followed by intravitreal injection of aflibercept 2mg in 0.05ml
2	Bialasiewicz, A A, et al. (2021) ²⁴ Case #2	CR	Qatar	50 (M)	Atopic dermatitis	mRNA vaccine (II)	15 minutes	LE	Retrolubar pain, red eye, vision reduction	0,5 (20/40)	FE, FA, OCT, VF	mild optic disc swelling, mild macular hemorrhages, CME, inferonasal VF defect	CRVO	Significant improvement of ME and BCVA (1,0 or 20/20) on the third day after acetylsalicylic acid 100mg/d and accompanied by intravitreal injection of aflibercept once a month
3	Endo, B., et al. (2021) ²⁵ Case #3	CR	Colombia	52 (M)	None	mRNA vaccine (I)	15 days	LE	Sudden blurred vision in the nasal and superotemporal quadrant for one day	20/20	FE, FA, OCT	Minimal dot hemorrhages in upper quadrants, dilated and tortuous veins in 4 quadrants, disperse exudates, occlusion in temporal branch	CRVO	BCVA remained (20/20), and significant improvement in hemorrhages after intravitreal injection of

No	Author (year) Case number #	Article Type	Country	Age (Sex)	Other medical condition	Vaccine Type (dose)	The time interval from vaccine to symptoms	Eye	Symptoms	Baseline BCVA	Eye Examination(s)	Fundal findings	Diagnosis	Outcome
														dexamethasone 0.4mg/o.1ml followed by intravitreal injection of bevacizumab 2.5mg/0.1ml and oral apixaban
4	Goyal, M., et al. (2021) ²⁶ Case #4	CR	India	28 (M)	None	Viral vector vaccine (II)	11 days	RE	Visual deterioration	20/32	IOP, FE, OCT	Superior hemiretinal vein occlusion with ME	HRVO	BCVA improved 3 days after oral prednisolone 40mg daily in tapering doses, and Apixaban 2.5mg twice daily for 6 weeks. Resolution of ME a week after.
5	Ikegami, Y., et al. (2021) ²⁷ Case #5	CR	Japan	54 (F)	Hypothyroidism	mRNA vaccine (II)	2 days	RE	Sudden severe vision loss	No LP	IOP, FE, OCT, OCTA, FA	Optic disc swelling, widespread flame-shaped hemorrhages in all four quadrants, whitening of the macula, attenuated retinal arteries, absence of vascular flow in foveal and perifoveal areas	CRVO + CRAO	Therapy and outcome are not reported
6	Tanaka, H., et al. (2021) ²⁸ Case #6-7	CR	Japan	71 (F)	BRVO + secondary ME	mRNA vaccine (I)	1 day	LE	Vision loss	20/30	UWPC, OCT	Vein occlusion in the temporal inferior branch, ME	BRVO	Resolution of ME after intravitreal injection of aflibercept and significant improvement

No	Author (year) Case number #	Article Type	Country	Age (Sex)	Other medical condition	Vaccine Type (dose)	The time interval from vaccine to symptoms	Eye	Symptoms	Baseline BCVA	Eye Examination(s)	Fundal findings	Diagnosis	Outcome
														of BCVA (20/20)
				74 (M)	BRVO	mRNA vaccine (I)	2 days	RE	Vision loss	20/25	UWPC, OCT	Vein occlusion in the temporal superior branch, ME	BRVO	Resolution of ME after 2 times of intravitreal ranibizumab
7	Cackett, P., et al. (2022) ²⁹ Case #8-9	CR	United Kingdom	44 (F)	None	Viral vector vaccine (I)	5 days	RE	two episodes of transient painless blurred vision	6/6 (20/20)	IOP, FE, OCT	Few scattered flame and blot hemorrhages in all quadrants	CRVO	Resolution of vein occlusion at 3-month follow up
				49 (F)	None	Viral vector vaccine (I)	4 days	RE	Blurred vision	6/12 (20/40)	IOP, FE, OCT	Few scattered blot hemorrhages in all quadrants, cotton wool spots	CRVO	Resolution of vein occlusion and BCVA improved (6/6 or 20/20) at 3- month follow up
8	Chen, YC. (2022) ³⁰ Case #10	CR	Taiwan	72 (M)	Elevated D- Dimer	mRNA vaccine (II)	8 days	RE	Sudden severe vision loss	HM	IOP, FE, FA, OCT	Extensive flame- shaped hemorrhages, attenuated retina arteries, retinal detachment, massive subretinal fluid at the macular area, ME	CRVO + CRAO	Significant improvement in BCVA (20/400) and retinal detachment after intravitreal injection of aflibercept 2mg/0.05ml and intravenous methylpredniso lone 1g/day for 3 days, followed with oral prednisolone 1g/kg/day, aspirin, and pan-retinal photocoagulation.

No	Author (year) Case number #	Article Type	Country	Age (Sex)	Other medical condition	Vaccine Type (dose)	The time interval from vaccine to symptoms	Eye	Symptoms	Baseline BCVA	Eye Examination(s)	Fundal findings	Diagnosis	Outcome
9	Dutta Majumder, P., et al. (2022) ³¹ Case #11	CR	India	28 (M)	None	Viral vector vaccine (III)	25 days	RE	Painless vision loss	2/60 (20/630)	FE, FA, OCT	Optic disc swelling, tortuous and dilated retinal vein, flame- shaped and dot dot retinal hemorrhages, the extensive cotton wool spot around the posterior pole, subretinal fluid, ME	CRVO	Resolution of optic disc swelling, ME, and most of the hemorrhages and significant improvement in BCVA (6/9 or 20/32) at 1- month follow- up after intravenous methylpredniso lone 1g for 3 days followed by oral corticosteroid 1 g/kg in tapering dose for 1 month.
10	Fernández-Vigo, J.I., et al. (2022) ³² Case #12-13	CR	Spain	69 (F)	None	Viral vector vaccine (I)	10 days	LE	Asymptomatic	20/20	FE, OCT, OCTA	Branch vein occlusion far from the macula	BRVO	Complete resolution after 6 weeks
					BRVO after the first vaccine	Viral vector vaccine (II)	30 days	RE	Sudden vision loss and central scotoma	20/100	FE, OCT, OCTA	A large number of hemorrhages, retinal detachment, ME	CRVO	Resolution of ME and worsened BCVA (20/200) after the first dose of dexamethasone intravitreal implant for 2 months, followed by a second dose of a new dexamethasone intravitreal implant for 1 month after ME recurred at

No	Author (year) Case number #	Article Type	Country	Age (Sex)	Other medical condition	Vaccine Type (dose)	The time interval from vaccine to symptoms	Eye	Symptoms	Baseline BCVA	Eye Examination(s)	Fundal findings	Diagnosis	Outcome
														4 months after the first dose.
11	Karageorgiou, G. et al. (2022) ³³ Case #14	CR	Greece	60 (M)	None	Viral vector vaccine (NR)	7 days	RE	Sudden painless vision loss of 24 hr duration	20/20	IOP, FE, FA, OCT	Optic disc swelling, peripapillary intraretinal hemorrhages, dilated and tortuous veins, intraretinal dot, blot, and flame-shaped hemorrhages in the upper temporal quadrant, intraretinal CME	BRVO	Intravitreal injection of anti-VEGF was given to treat the ME. The outcome after the therapy was not reported
12	Lee, S., et al. (2022) ³⁴ Case #15	CR	USA	34 (M)	HL, mildly elevated ESR	mRNA vaccine (II)	10-12 days	LE	Blurred vision and decreased vision	CF	FE, FA, OCT	Optical disc swelling, dilated and tortuous retinal vein, few scattered blot hemorrhages in 4 quadrants, exudative macular detachment on the macula, delayed retinal arterial and vein filling	CRVO + CRAO	The patient was treated with hyperbaric oxygen, followed by intravitreal injection of aflibercept, dexamethasone, bromfenac, and acetazolamide after ME was present, followed by oral methylprednisolone to respond to the mildly elevated ESR. Optic disc swelling worsened, and vision darkened, and the patient was

No	Author (year) Case number #	Article Type	Country	Age (Sex)	Other medical condition	Vaccine Type (dose)	The time interval from vaccine to symptoms	Eye	Symptoms	Baseline BCVA	Eye Examination(s)	Fundal findings	Diagnosis	Outcome
														treated with self-administered 80mg/0.8mL of LMWH which was switched to apixaban, followed by a high dose of IV methylprednisolone 1g/day for 3 days. Significant improvement of BCVA (20/30) after the treatment continued with oral prednisolone tapered beginning at 80mg QD, followed by pentoxifylline 400mg BID because of the persistent disc swelling. The patient additionally diagnosed with NAION
13	Noguchi, K., et al. (2022) ³⁵ Case #16	CR	Japan	46 (F)	None	mRNA vaccine (II)	NR	RE	6-day history of visual disturbance	12/20 (20/32)	FE	Dilated and tortuous vein, dispersed dot, and flame-shaped hemorrhages	CRVO	Resolution of BCVA (20/20) at 3 months follow up after intravitreal injection of ranibizumab
14	Parakh, S., et al. (2022) ³⁶ Case #17	CR	India	31 (M)	Hyperhomocysteinemia	Viral vector vaccine (I)	7 days	LE	Painless vision loss	6/9 (20/32)	IOP, FE, SW-FAF, SD-OCT, OCTA	Optic disc hyperemia, dilated and tortuous vein, superficial and	CRVO	BCVA remained 6/9 (20/32), with a resolution of

No	Author (year) Case number #	Article Type	Country	Age (Sex)	Other medical condition	Vaccine Type (dose)	The time interval from vaccine to symptoms	Eye	Symptoms	Baseline BCVA	Eye Examination(s)	Fundal findings	Diagnosis	Outcome
												deep intraretinal hemorrhages in 4 quadrants, a few cotton-wool spots, CME		CME, and normalized serum homocysteine at 18 months follow up after being treated with oral folic acid B6 and B12 vitamin supplementation, 4 intravitreal injections of anti-VEGF ranibizumab for 8 months, followed by 3 intravitreal anti-VEGF aflibercept
15	Priluck, A., et al. (2022) ³⁷ Case #18	CR	USA	57 (F)	HTN, dry eye syndrome	mRNA vaccine (II)	NR	LE	Flashes and floaters	20/20	IOP, FE	Superotemporal branch retinal vein occlusion, superficial intraretinal hemorrhages scattered along the superior arcade	BRVO	ME developed and BCVA worsened (20/30) after observation for 5 weeks. Persistent ME and BCVA improved (20/25) after intravitreal injections of aflibercept monthly for 6 months
16	Pur, DR., et al. (2022) ³⁸ Case #19	CR	Canada	34 (M)	None	mRNA vaccine (I)	2 days	RE	Blurred vision in the inferior visual field and intermittent photopsia	20/20	FE, FA, OCT	Dilated and tortuous superior nasal branch retinal vein, multiple retinal hemorrhages, cotton wool spots	BRVO	New macular exudates, resolution of intraretinal hemorrhages, and BCVA remained (20/20), and

No	Author (year) Case number #	Article Type	Country	Age (Sex)	Other medical condition	Vaccine Type (dose)	The time interval from vaccine to symptoms	Eye	Symptoms	Baseline BCVA	Eye Examination(s)	Fundal findings	Diagnosis	Outcome
														inferior visual field defect at follow-up after 4, 7, and 10 months.
17	Romano, D., et al. (2022) ³⁹ Case #20	CR	Italy	54 (F)	HTN	Viral Vector vaccine (II)	2 days	RE	Painless loss of vision	20/400	FE, FA, OCT	Retinal hemorrhages in all quadrants, dilated and tortuous retinal vein, optic disc swelling, and diffuse ME	CRVO	Significant improvement of BCVA (20/200) after intravitreal implant of dexamethasone and argon laser panretinal photocoagulation.
18	Ruiz, OA., et al. (2022) ⁴⁰ Case #21	CR	Spain	51 (F)	hypothyroidism	mRNA vaccine (II)	12 days	LE	Blurred vision and increasing "grey patches" in the left inferior visual field	8/10 (20/25)	IOP, FE, OCT	Optic disc swelling, peripapillary flame-shaped hemorrhages, widespread dot and blot retinal hemorrhages, retinal edema, occlusion in the superior temporal branch of the retinal artery and central retinal vein	CRVO + BRAO	BCVA worsened (3/10 or 20/63) at the one-month follow-up and remained stable at the two-month follow-up.
19	Sacconi, R., et al. (2022) ⁴¹ Case #22	CR	Italy	74 (F)	Breast cancer, AF	mRNA vaccine (II)	48 hours	RE	Painless vision loss	20/32	IOP, FE, FA, OCT,	Venous congestion, widespread blot hemorrhages in the inferior quadrants	HRVO	BCVA worsened (20/40), and CME was present at a 3-week follow-up. BCVA improved (20/32) and the resolution of ME after 2 intravitreal injections of

No	Author (year) Case number #	Article Type	Country	Age (Sex)	Other medical condition	Vaccine Type (dose)	The time interval from vaccine to symptoms	Eye	Symptoms	Baseline BCVA	Eye Examination(s)	Fundal findings	Diagnosis	Outcome
														ranibizumab at the 5-week examination
20	Sodhi, PK., et al. (2022) ⁴² Case #23	CR	India	43 (M)	Slightly raised glycosylated hemoglobin	Viral vector vaccine (I)	3 days	LE	Sudden painless vision loss	20/630	IOP, FE, FA, OCT, OCTA	Optic disc swelling, dilated and tortuous vein veins, dot-blot and flame-shaped hemorrhages across the fundus, enlarged foveal avascular zone, CFT thickening, CME	CRVO	Significant improvement in BCVA (20/200) and resolution of hemorrhages and exudates, and CFT reduced at 6-month follow-up after intravitreal injection of triamcinolone acetonide (4mg/0.1ml). Neovascularization was found and treated with a targeted laser
21	Sonawane, N., et al. (2022) ⁴³ Case #24-25	CR	India	50 (M)	DM, elevated blood urea, creatinine, HbA1C	Viral vector vaccine (II)	4 days	RE	Vision loss	6/60 (20/200)	IOP, FE, OCT	Optic disc swelling, dilated and tortuous veins, diffuse retinal hemorrhages, CME	CRVO	The patient was treated with an intravitreal injection of anti-VEGF. No outcome was reported
				43 (F)	Elevated CRP, Rheumatoid factor, d-Dimer	Viral vector vaccine (II)	3 days	RE	Sudden vision loss	5/60 (20/250)	IOP, FE, OCT	Optic disc swelling, tortuous veins, intraretinal hemorrhages in 4 quadrants,	CRVO	The patient received no treatment (observation only). No outcome was reported
22	Sugihara, K., et al. (2022) ⁴⁴ Case #26	CR	Japan	38 (M)	None	mRNA vaccine (II)	2 days	LE	Vision loss	0.9 (20/25)	FE, FA, OCT	Retinal hemorrhages and cotton wool spots in the	BRVO	Improvement in BCVA (1.2 or 20/16) and resolution of

No	Author (year) Case number #	Article Type	Country	Age (Sex)	Other medical condition	Vaccine Type (dose)	The time interval from vaccine to symptoms	Eye	Symptoms	Baseline BCVA	Eye Examination(s)	Fundal findings	Diagnosis	Outcome
												superotemporal region of the posterior pole, ME		retinal hemorrhages and ME at 7 months after the initial visit after 2 intravitreal injections of anti-VEGF 2mg/0.05ml aflibercept.
23	Takacs, A., et al. (2022) ⁴⁵ Case #27	CR	Hungary	35 (M)	Serum prothrombin slightly reduced, antithrombin activity slightly elevated, serum homocystein slightly elevated, mild aortic insufficiency.	mRNA vaccine (I)	2 weeks	RE	Visual decrease	20/40	OCT	Papilledema, cystoid ME, elevated RNFL thickness	CRVO	BCVA improved to 20/20 and ME resolved after an oral ASA (100mg daily) and a single dose of intravitreal anti-VEGF (aflibercept).
24	Tanaka, H., et al. (2022) ⁴⁶ Case #28-29	CR	Japan	50 (F)	Breast cancer	mRNA vaccine (I)	3 days	RE	Vision loss	20/25	UWPC, OCT, OCTA	Flame-shaped hemorrhages around the temporal superior retinal vein, ME	BRVO	Resolution of ME and significant improvement of BCVA (20/20) at 2-month follow-up after 3 doses of intravitreal ranibizumab.
				56 (F)	None	mRNA vaccine (I)	3 days	RE	Vision loss	13/20 (20/32)	UWPC, OCT, OCTA	Flame-shaped hemorrhage around the temporal inferior retinal vein, ME	BRVO	Resolution of ME and significant improvement of BCVA (20/20) at 2-month follow-up after 3

No	Author (year) Case number #	Article Type	Country	Age (Sex)	Other medical condition	Vaccine Type (dose)	The time interval from vaccine to symptoms	Eye	Symptoms	Baseline BCVA	Eye Examination(s)	Fundal findings	Diagnosis	Outcome
														doses of intravitreal ranibizumab.
25	Bolletta, E., et al. (2021) ⁴⁷ Case #30-34	CS	Italy	39 (M)	None	mRNA vaccine (II)	30 days	RE	Decreased vision	20/400	NR	NR	CRVO	Mild improvement of BCVA (20/100) after intravitreal anti-VEGF
				53 (F)	SAH	Viral vector vaccine (I)	2 days	LE	Decreased vision	20/100	NR	NR	BRVO	Partial improvement of BCVA (20/40) after intravitreal anti-VEGF
				61 (F)	None	Viral vector vaccine (II)	2 days	LE	Decreased vision	20/32	NR	NR	BRVO	Partial improvement of BCVA (20/25) after intravitreal anti-VEGF
				50 (M)	DM	mRNA vaccine (II)	3 days	LE	Decreased vision	20/32	NR	NR	BRVO	significant improvement of BCVA (20/20) after intravitreal anti-VEGF
				48 (M)	SAH	mRNA vaccine (II)	23 days	LE	Blurred vision	20/32	NR	NR	BRVO	significant improvement of BCVA (20/20) after intravitreal anti-VEGF
26	Girbardt, C., et al. (2021) ⁴⁸ Case #35-36	CS	NR	81 (F)	HTN	mRNA vaccine (II)	12 days	RE	Blurred vision and unsteadiness	20/400	FE, FFA, OCT	Multiple intraretinal hemorrhages	RVO + RAO	NR
						mRNA vaccine (II)	12 days	LE	NR	20/80	FE, FFA, OCT	Hard exudates, centrally localized hemorrhage, ME	BRVO	The patient received anti-VEGF. The outcome was not reported.

No	Author (year) Case number #	Article Type	Country	Age (Sex)	Other medical condition	Vaccine Type (dose)	The time interval from vaccine to symptoms	Eye	Symptoms	Baseline BCVA	Eye Examination(s)	Fundal findings	Diagnosis	Outcome
27	Park, HS., et al. (2021) ⁴⁹ Case #37-47	CS	South Korea	68 (F)	Dyslipidemia, vitreous hemorrhage	Viral vector vaccine (I)	1 day	LE	NR	HM	NR	NR	RVO	The patient was observed. The outcome was not reported.
				76 (M)	HTN, Cataract, NTG	mRNA vaccine (I)	3 days	LE	NR	20/25	NR	NR	RVO	The patient was observed. The outcome was not reported.
				85 (F)	DM, HTN, ESRD, tuberculosis, dementia, vitreous hemorrhage	mRNA vaccine (II)	1 day	RE	NR	CF	NR	NR	RVO	The patient received anti- VEGF (Bevacizumab) . The outcome was not reported.
				59 (M)	DM, HTN	Viral vector vaccine (I)	2 days	LE	NR	20/25	NR	NR	RVO	The patient was observed. The outcome was not reported.
				61 (M)	None	Viral vector vaccine (I)	2 days	RE	NR	20/500	NR	NR	RVO	The patient received anti- VEGF (Bevacizumab) . The outcome was not reported.
				79 (M)	DM, gastric cancer	mRNA vaccine (II)	2 days	LE	NR	20/500	NR	NR	RVO	The patient received anti- VEGF (Bevacizumab) . The outcome was not reported.
				77 (F)	HTN, Hepatitis B Virus Carrier, colon cancer on chemotherapy, cataract	mRNA vaccine (I)	16 days	LE	NR	20/25	NR	NR	RVO	The patient received anti- VEGF (Bevacizumab) . The outcome was not reported.

No	Author (year) Case number #	Article Type	Country	Age (Sex)	Other medical condition	Vaccine Type (dose)	The time interval from vaccine to symptoms	Eye	Symptoms	Baseline BCVA	Eye Examination(s)	Fundal findings	Diagnosis	Outcome
				63 (M)	DM, DME	mRNA vaccine (I)	13 days	RE	NR	CF	NR	NR	RVO	The patient received anti- VEGF (Bevacizumab) . The outcome was not reported.
				51 (F)	HTN	Viral vector vaccine (I)	21 days	LE	NR	20/180	NR	NR	RVO	The patient received anti- VEGF (Bevacizumab) . The outcome was not reported.
				81 (F)	HTN, cataract	mRNA vaccine (I)	4 days	LE	NR	20/63	NR	NR	RVO	The patient was observed. The outcome was not reported.
				61 (M)	HTN, uveitis	Viral vector vaccine (I)	3 days	LE	NR	20/25	NR	NR	RVO	The patient was observed. The outcome was not reported.
28	Silva, LSC., et al. (2021) ⁵⁰ Case #48-51	CS	Brazil	66 (F)	Endometrial hypertrophy, overweight, increased apolipoprotein a	Viral vector vaccine (NR)	16 days	RE	Headache	NR	FE, OCT	Superotemporal intraretinal hemorrhages, ME	BRVO	NR
			Spain	51 (M)	COVID-19 infection 10 months prior	mRNA vaccine (NR)	6 days	LE	None	NR	FE, OCT	Diffuse intraretinal hemorrhages, ME	CRVO	NR
			Brazil	66 (M)	HTN	Viral vector vaccine (NR)	4 days	NR	None	NR	NR	NR	RVO	NR
			Brazil	54 (F)	None	Viral vector vaccine (NR)	10 days	NR	None	NR	NR	NR	RVO	NR
29	Choi, M., et al. (2022) ⁵¹ Case #52-59	CS	South Korea	64 (M)	None	Viral vector	1 day	RE	NR	20/25	NR	NR	CRVO	The patient was observed with aspirin.

No	Author (year) Case number #	Article Type	Country	Age (Sex)	Other medical condition	Vaccine Type (dose)	The time interval from vaccine to symptoms	Eye	Symptoms	Baseline BCVA	Eye Examination(s)	Fundal findings	Diagnosis	Outcome
						vaccine (I)								The outcome was not reported
				33 (F)	None	mRNA vaccine (II)	6 days	RE	NR	20/40	NR	NR	CRVO	The patient received an anti-VEGF injection. The outcome was not reported
				48 (M)	None	mRNA vaccine (III)	6 days	RE	NR	20/125	NR	NR	CRVO	The patient received an anti-VEGF injection. The outcome was not reported
				69 (F)	None	Viral vector vaccine (I)	3 days	LE	NR	20/20	NR	NR	BRVO	The patient was observed with aspirin. The outcome was not reported
				66 (M)	None	Viral vector vaccine (II)	7 days	LE	NR	20/20	NR	NR	BRVO	The patient was observed without any treatment. The outcome was not reported
				68 (F)	BRVO	Viral vector vaccine (I)	1 day	RE	NR	HM	NR	Vitreous hemorrhage	BRVO	The patient was observed without any treatment. The outcome was not reported
				74 (F)	HTN, Nasal cavity Cancer, BRVO	Viral vector vaccine (II)	6 days	RE	NR	HM	NR	Vitreous hemorrhage	BRVO	The patient received a vitrectomy. The outcome was not reported
				63 (F)	CRVO	Viral vector vaccine (I)	3 days	LE	NR	20/630	NR	NR	CRVO	The patient received an anti-VEGF injection. The

No	Author (year) Case number #	Article Type	Country	Age (Sex)	Other medical condition	Vaccine Type (dose)	The time interval from vaccine to symptoms	Eye	Symptoms	Baseline BCVA	Eye Examination(s)	Fundal findings	Diagnosis	Outcome
														outcome was not reported
30	Peters, MC., et al. (2022) ⁵² Case #60-64	CS	Australia	71 (M)	None	Viral vector vaccine (I)	48 hour	NR	Visual disturbances	20/200	NR	ME	BRVO	The patient received monthly intravitreal anti-VEGF (Bevacizumab). The outcome was not reported.
				58 (M)	Pterygium	Viral vector vaccine (I)	72 hour	NR	Visual disturbances	20/63	NR	ME	HRVO	The patient received monthly intravitreal anti-VEGF (Bevacizumab). The outcome was not reported.
				73 (F)	Retinal detachment, HTN	Viral vector vaccine (I)	72 hour	NR	Visual disturbances	20/63	NR	ME	BRVO	The patient received monthly intravitreal anti-VEGF (Aflibercept). The outcome was not reported.
				47 (F)	Hyperthyroidism	mRNA vaccine (I)	5 days	NR	Visual disturbances	20/32	NR	ME	BRVO	The patient received monthly intravitreal anti-VEGF (Bevacizumab). The outcome was not reported.
				36 (M)	None	mRNA vaccine (II)	24-72 hour	NR	Visual disturbances	20/32	NR	ME	CRVO	The patient received monthly intravitreal anti-VEGF

No	Author (year) Case number #	Article Type	Country	Age (Sex)	Other medical condition	Vaccine Type (dose)	The time interval from vaccine to symptoms	Eye	Symptoms	Baseline BCVA	Eye Examination(s)	Fundal findings	Diagnosis	Outcome
														(Aflibercept). The outcome was not reported.
31	Vujosevic, S., et al. (2022) ⁵³ Case #65-78	CS	Italy	69 (F)	DVT	Viral vector vaccine (I)	1 week	RE	NR	20/32	IOP, FE, OCT, OCTA, FFA	Hemorrhage +, quadrant ischemia, inferotemporal branch vein occlusion	BRVO	BCVA improved (20/20) after receiving laser photocoagulation
				82 (F)	None	mRNA vaccine (II)	2 weeks	RE	NR	20/63	IOP, FE, OCT, OCTA, FFA	Edema +++, hemorrhages +, quadrant ischemia, inferotemporal branch vein occlusion	BRVO	BCVA improved (20/40) after receiving steroid treatment
				96 (F)	HTN, DM	mRNA vaccine (II)	1 week	RE	NR	20/200	IOP, FE, OCT, OCTA, FFA	Edema +++, SND, hemorrhages ++	CRVO	Persistent BCVA (20/200) after steroid treatment
				91 (F)	None	mRNA vaccine (II)	1.5 week	LE	NR	CF	IOP, FE, OCT, OCTA, FFA	IOI, edema +++, hemorrhages +++,	CRVO	Persistent BCVA (CF) at the last follow- up (unknown time) after the patient refused any treatment
				78 (F)	None	mRNA vaccine (II)	1 week	RE	NR	20/25	IOP, FE, OCT, OCTA, FFA	Edema +, hemorrhages +, superotemporal branch retinal vein occlusion	BRVO	BCVA improved (20/20) after receiving anti- VEGF agents
							1 week	LE	NR	20/20	IOP, FE, OCT, OCTA, FFA	Hemorrhages +, superotemporal branch retinal vein occlusion	BRVO	BCVA remained 20/20 with no treatment
				70 (M)	None	Viral vector vaccine (I)	1 week	RE	NR	20/20	IOP, FE, OCT, OCTA, FFA	Hemorrhages +	CRVO	BCVA remained 20/20 with no treatment
				40 (M)	Hyperhomocysteinemia	Viral vector	2 weeks	RE	NR	20/20	IOP, FE, OCT,	Hemorrhages +	BRVO	BCVA remained

No	Author (year) Case number #	Article Type	Country	Age (Sex)	Other medical condition	Vaccine Type (dose)	The time interval from vaccine to symptoms	Eye	Symptoms	Baseline BCVA	Eye Examination(s)	Fundal findings	Diagnosis	Outcome
						vaccine (I)					OCTA, FFA			20/20 with no treatment
				91 (M)	DM	mRNA vaccine (II)	4 weeks	RE	NR	20/32	IOP, FE, OCT, OCTA, FFA	Edema +++, SND	BRVO	Persistent BCVA (20/32) after receiving steroid treatment
				72 (F)	HTN, HL	mRNA vaccine (II)	3 weeks	RE	NR	20/25	IOP, FE, OCT, OCTA, FFA	Edema +, hemorrhages +, quadrant ischemia, superotemporal branch retinal vein occlusion	BRVO	BCVA improved (20/20) after receiving steroid treatment
				88 (M)	HTN, HL, CVD, Alzheimer, Prostate cancer	mRNA vaccine (II)	2 weeks	RE	NR	20/125	IOP, FE, OCT, OCTA, FFA	Edema ++, hemorrhages +, hemispheric retinal vein occlusion	HRVO	Persistent BCVA (20/125) after receiving steroid treatment
				73 (F)	HTN, HL, CVD, NET	Viral vector vaccine (II)	4 weeks	RE	NR	CF	IOP, FE, OCT, OCTA, FFA	Edema +, hemorrhages +	CRVO	Persistent BCVA (CF) after receiving steroid treatment
				65 (F)	HTN, HL, DM	Viral vector vaccine (I)	1 week	RE	NR	20/40	IOP, FE, OCT, OCTA, FFA	Edema +, small SND, hemorrhages +	CRVO	BCVA improved (20/32) after receiving steroid treatment
				72 (F)	HTN, CVD	Viral vector vaccine (I)	2 weeks	LE	NR	20/50	IOP, FE, OCT, OCTA, FFA	Hemorrhages +++, superior quadrants ischemia, hemispheric retinal vein occlusion	HRVO	Persistent BCVA (20/50) after receiving laser photocoagulation

Abbreviation: AF, atrial fibrillation; anti-VEGF, anti-vascular endothelial growth factor; BCVA, best corrected visual acuity; BRVO, branch retinal vein occlusion; COVID-19, Coronavirus Disease-19; CRVO, Central retinal vein occlusion; CVD, cardiovascular disease; DM, diabetes mellitus; DME, diabetic macular edema; DVT, deep vein thrombosis; ESRD, End stage renal disease; FA, fluorescein angiography; FE, fundal examination; FFA, Fundus fluorescein angiography; HL, hyperlipidemia; HTN, hypertension; HRVO, hemispheric retinal vein occlusion; IOP, intraocular pressure; LE, left eye; ME, macular edema; NET, neuroendocrine tumour; NR, not reported; NTG,

Normal Tension Glaucoma; OCT, Optical coherence tomography; OCTA, Optical coherence tomography angiography; RE, right eye; RVO, retinal vein occlusion; SAH, subarachnoid hemorrhage; UWPC, ultra-wide-field pseudo-color; VF, visual field;